Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price reduced by Bank of America from $30.00 to $28.00 in ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) were down 8.9% during trading on Monday after Bank of America lowered their price target on the stock from $30.00 to $28.00. Bank of ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Denali Therapeutics Inc.’s DNLI share price has dipped by 10.43%, which has investors questioning if this is right time to buy.

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

Creating A New Standard For Treating CNS DiseaseInhibikase Therapeutics (NASDAQ:IKT) is a biotechnology company focused on creating new therapies for Central Nervous System (CNS) ...

In this article, we are going to take a look at where Denali Therapeutics Inc. (NASDAQ:DNLI) stands against the other companies Bezos is investing in. Since leaving his position as CEO of Amazon ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug. Denali Therapeutics showcases ...

Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...